Pfizer had been counting on torcetrapib to make up for several patent Lipitor patent expiration expirations, including one on cholesterol-lowering Lipitor, Pfizer’s top-selling product with $12 billion in annual sales. Even before the trial halt, Pfizer had said it would lipitor patent expiration cut its sales force by 20%, or 2,200 jobs. The deal, which has drawn mass intrigue and some ire from both industry and media, could represent the first steps to replacing the conventional pharma sales model with something much cheaper and more effective. Another drug to treat schizophrenia is in the works, and approval is expected this month. Visit http://www. Com/performance for information about the performance numbers displayed in this press release. If all goes to plan, Pfizer will be able to detail physicians on their own terms and at their own convenience. There are two drugs in phase III development right now that really have the potential to be this type of company changing product. Pharmaceutical industry, citing the loss of billions of dollars Lipitor patent expiration for companies such as Pfizer Inc. Acute coronary syndrome would compete with Plavix, a $4 billion a year drug. Celebrex and Bextra benefited from lipitor patent expiration the withdrawal of Merck & Co. ’s competitor lipitor patent expiration vioxx from the market because the drug doubled patients’ risk of heart attack and strokes. In other words, it’s still too early to tell how this new market will shape up. As many as 65 percent of people suffering from high cholesterol don t treat their condition, said David Shedlarz, Pfizer’s executive vice president and chief financial officer, in a presentation he gave last lipitor patent expiration month. Credit rating company, which evaluates 21 U. Pfizer’s sales force is very well-entrenched, probably the most well-entrenched sales force in the cardiovascular area, Lipitor patent expiration moskowitz noted. When that drug loses patent protection around 2010, along with it will go most of the $10 billion it brings to Pfizer’s coffers. Wyeth will market Bifeprunox in the United States, in collaboration with the drug’s lipitor patent expiration developer, Solvay of Belgium.